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involved in a variety of inflammatory
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Matrix metalloproteinase-2 (MMP-2) is involved in
several physiological mechanisms, including wound
healing and tumor progression. We show that
MMP-2 directly stimulates dendritic cells (DCs) to
both upregulate OX40L on the cell surface and
secrete inflammatory cytokines. The mechanism un-
derlying DC activation includes physical association
with Toll-like receptor-2 (TLR2), leading to NF-kB
activation, OX40L upregulation on DCs, and ensuing
TH2 differentiation. Significantly, MMP-2 polarizes
T cells toward type 2 responses in vivo, in a TLR2-
dependent manner. MMP-2-dependent type 2 polar-
ization may represent a key immune regulatory
mechanism for protection against a broad array of
disorders, such as inflammatory, infectious, and
autoimmune diseases, which can be hijacked by
tumors to evade immunity.INTRODUCTION
Matrix metalloproteinases (MMPs) are zinc-dependent endo-
peptidases. They can degrade extracellular matrix proteins,
participate in the cleavage of cell-surface receptors and chemo-
kines or cytokines, and modulate cell proliferation, migration,
differentiation, and angiogenesis. MMP-2, a member of the ge-
latinase subfamily of MMPs, participates in the remodeling and
resolution of tissue injury (Bian and Sun, 1997; Brooks et al.,
1998), embryonic development and morphogenesis (Seshagiri
et al., 2003), infection clearance (Atarashi et al., 2011; D’Angelo
et al., 2001; Lima et al., 2012), and tumorigenesis (Coussens and
Werb, 2002; Egeblad and Werb, 2002; Hanahan and Weinberg,
2000; Liotta et al., 1980; Westermarck and Ka¨ha¨ri, 1999).1856 Cell Reports 9, 1856–1870, December 11, 2014 ª2014 The AutWe recently identified an unexpected role for MMP-2 in the
modulation of innate immune function and in the differentiation
of inflammatory TH2 responses. MMP-2 pre-exposure inhibits
interleukin-12 (IL-12) function and upregulates OX40L expres-
sion by human dendritic cells (DCs) (Godefroy et al., 2011). Enzy-
matically active MMP-2 causes degradation of the IFNAR1 chain
of the type 1 interferon (IFN) receptor, reducing the ability of
IFN-b to enhance transcription of the IL-12p35 subunit through
STAT1 phosphorylation (Godefroy et al., 2011). In the absence
of IL-12, OX40L now functions as a key costimulatory molecule
for the priming of TH2 cells (Ito et al., 2005; Soumelis et al.,
2002). However, the mechanism by which MMP-2 upregulates
OX40L is not known, and the role of MMP-2-driven TH2 cells
in vivo has not been determined.
MMP-2 overexpression is observed in certain infections where
eradication and control of immunopathogenesis rely on the
development of protective type 2 responses (Oakley et al.,
2013; Sauer et al., 2013). For instance, various parasites
including plasmodium (Lima et al., 2012) and toxoplasma (Lu
and Lai, 2013) species can trigger MMP-2 overexpression. As
another example, MMP-2 plays a central role during wound heal-
ing and repair (Bian and Sun, 1997; Brooks et al., 1998). Inflam-
matory TH2 cytokines (tumor necrosis factor alpha [TNF-a], IL-4,
and IL-13) have been described as essential components in this
process (Chen et al., 2012). Last, MMP-2, which is overex-
pressed in tumors, promotes cancer progression (Egeblad and
Werb, 2002; Hofmann et al., 2000), and our prior studies suggest
that this may in part be due to its ability to skew type 2 polariza-
tion (Godefroy et al., 2011). These observations suggest that
MMP-2, through its ability to drive TH2 cells, plays a unique
role in modulating effector T cell responses.
In this study, we specifically investigated mechanisms by
which MMP-2 upregulates OX40L on DCs to drive type 2 polar-
ization. We identified a physiological receptor for MMP-2 on DCs
that, upon activation, leads to TH2 polarization. Therefore, extra-
cellular MMP-2 has the potential to locally affect DCs leading tohors
modulation of immune responses during infectious, inflamma-
tory, or malignant diseases.
RESULTS
MMP-2 Induces Human DCs to Upregulate OX40L and
Secrete Inflammatory Cytokines
To better understand how MMP-2 influences DC function,
we first characterized levels of OX40L expression on DCs
pre-exposed to MMP-2. Unexpectedly, heat-inactivated (HI)
MMP-2 or MMP-2 preincubated with a specific inhibitor induced
human monocyte-derived DCs (moDCs) to upregulate OX40L at
48 hr, and to a lesser extent at 24 hr (Figure 1A), similar to what
was observedwith enzymatically activeMMP-2. Enzymatic inac-
tivity of HI-MMP-2 was verified as previously described (Godef-
roy et al., 2011). MMP-9 and the MMP-2 vehicle control did not
affect OX40L expression (Figure 1A), suggesting that MMP-2
protein, but not its closely related familymemberMMP-9, specif-
ically upregulates OX40L.
MMP-2-exposed moDCs also secreted significant levels of in-
flammatory cytokines such as TNF-a, IL-6, and IL-8 (p < 0.02
compared to vehicle control or inhibitor alone; Figure 1B), but
not IL-12 (data not shown). Once again, both active and inacti-
vated MMP-2, but none of the controls, stimulated moDCs (Fig-
ure 1B). Purified blood DCs were similarly activated by MMP-2
(Figure S1). These experiments show that MMP-2 induces hu-
man DCs to secrete inflammatory cytokines and that activation
of DCs is independent of MMP-2’s enzymatic activity.
MMP-2 Activates the Canonical NF-kB Pathway
OX40L expression is modulated by molecules such as TSLP (Ito
et al., 2005), Toll-like receptor 2 (TLR2) and TLR4 agonists, e.g.,
zymosan, lipopolysaccharide (LPS) (Han et al., 2011), and short
ragweed pollen (Li et al., 2011). Upregulation of OX40L requires
activation of the NF-kBpathway, which is also integral to the pro-
duction of proinflammatory cytokines. Using a cell-permeable
NEMO-binding domain (NBD) peptide, which inhibits the prox-
imal NEMO molecule of the canonical NF-kB signaling pathway
(May et al., 2000), we confirmed the significance of this pathway
inMMP-2-induced inflammatory cytokine production (Figure 2A)
and OX40L upregulation (Figure 2B) by moDCs (p < 0.05).
To better characterize which components of the NF-kB
pathway were implicated, we monitored the translocation of
NF-kB transcription factors into the nucleus of DCs after
MMP-2 stimulation. MMP-2 induced significant translocation
of p50 and p65/RelA (p < 0.05), but not c-Rel, p52, or RelB
from the cytosol to the nucleus (Figures 2C and 2D). Thus,
MMP-2 activates the canonical pathway in human DCs, which
underlies the upregulation of OX40L and production of inflamma-
tory cytokines.
MMP-2 Triggers the Toll-like Receptor 2
We next evaluated which receptors facilitated MMP-2-mediated
upregulation of inflammation and OX40L. TSLP as well as TLR2
and TLR4 agonists can increase OX40L expression through
NF-kB activation (Arima et al., 2010; Han et al., 2011; Ito et al.,
2005; Li et al., 2011). Neither TSLP (Arima et al., 2010) nor TNF-
a (a control for NF-kB activation) induced OX40L upregulationCell Reon moDCs (Figure S2). Compared to active and HI-MMP-2,
only zymosan and MALP2 (TLR2/6 agonists), but not Pam3CSK4
(TLR2/1 agonist) or other agonists (for TLR3, TLR4, TLR5, and
TLR7/8), upregulated OX40L expression on moDCs (Figure 3A).
These results suggest that MMP-2 stimulates DCs via TLR2/6.
TLR2 expression on moDCs and mDCs was confirmed by flow
cytometry (Figure 3B). A blocking antibody for TLR2, but surpris-
ingly not an anti-TLR6, significantly inhibited MMP-2-induced
cytokine production andOX40L upregulation bymoDCs (Figures
3C and 3D). Importantly, the vehicle control did not activate
moDCs indicating that MMP-2 itself rather than a contaminant
was responsible for this effect. A role for heat-resistant contam-
inants was further excluded using proteinase K-degraded
MMP-2, which failed to activate NF-kB or upregulate OX40L
(Figures S3A and S3B) in TLR2-expressing HEK-Blue cells.
MMP-2 degradationwas confirmed by SDS-PAGE andCoomas-
sie staining (Figure S3C). Furthermore, supernatants fromMMP-
2-secreting melanoma cells directly induced NF-kB activation
and OX40L upregulation (Figures S3D–S3G), further reducing
the likelihood of potential contaminant involvement. Together,
these results show that MMP-2 specifically triggers TLR2, inde-
pendently of TLR6, on moDCs, which leads to NF-kB activation,
inflammatory cytokine secretion, and OX40L upregulation.
We also used HEK-Blue cells stably cotransfected with human
tlr genes and the secreted embryonic alkaline phosphatase gene
placed under control of the NF-kB promoter (‘‘Blue’’ technology,
InvivoGen) to test MMP-2’s specificity. MMP-2 and various
TLR2/6 (zymosan and MALP2) or TLR2/1 (Pam3CSK4) agonists
significantly activated NF-kB and IL-8 production (p % 0.0001)
in TLR2-transfected HEK-Blue cells, which express endogenous
TLR1 and TLR6 (Figure 4A, black bars). As in moDCs (Figure 3),
MMP-2-mediated activation of TLR2-transfected HEK-Blue cells
was inhibited upon TLR2 blocking (p < 0.005 and p < 0.00003 for
NF-kB and IL-8 inhibition, respectively; Figure 4A, gray bars).
The anti-TLR6 blocking antibody had no effect on MMP-2-acti-
vated HEK cells but blocked zymosan and MALP2 stimulation
(p < 0.05; Figure 4A, striped bars). Moreover, neither MMP-2
nor the TLR2 agonists activated NF-kB in the TLR1+/TLR6+
parental HEK-Blue cell line (Null-HEK-Blue), which was not
transfected with TLR2 (Figure 4B), highlighting the specificity of
MMP-2 for TLR2. To further control for contaminants (e.g., endo-
toxins), we used TLR4-transfected HEK-Blue cells. MMP-2 did
not activate NF-kB in these cells (Figure 4C). Likewise, MMP-
2-induced OX40L upregulation was observed in TLR2-express-
ing HEK cells and inhibited with a blocking antibody to TLR2
(Figure 4D). As expected, MMP-2 did not upregulate OX40L
on either Null-HEK (Figure 4E) or TLR4-transfected HEK cells
(Figure 4F).
Altogether, these data indicate that MMP-2 specifically trig-
gers TLR2 independently of TLR6 or TLR1, which leads to
NF-kB activation, inflammatory cytokine secretion, and OX40L
upregulation.
MMP-2 Is a Ligand for TLR2
We next assessed whether MMP-2 directly interacts with TLR2.
Both MMP-2 and MyD88 immunoprecipitated with TLR2 when
TLR2-transfected HEK cells were pretreated with MMP-2 (active
or inactive), but not with MMP-9 (Figure 5A; p < 0.02 comparedports 9, 1856–1870, December 11, 2014 ª2014 The Authors 1857
Figure 1. MMP-2 Upregulates OX40L Expression and Inflammatory Cytokine Secretion by Human moDCs
ImmaturemoDCswere cultured with enzymatically active or inactiveMMP-2 (0.5 and 5 mg/ml). MMP-2was inactivated either by heat treatment (HI) or by adding a
specific inhibitor (MMP-2+inh.) as described in Experimental Procedures. The vehicle control or MMP-9 (0.5 and 5 mg/ml) served as controls.
(A) After 24 and 48 hr, OX40L expressionwas assessed by surface staining onCD11chigh gated cells. An isotypemAbwas used as a negative control. MoDCs from
a representative donor out of three is shown.
(B) Inflammatory cytokines (TNF-a, IL-6, and IL-8) weremeasured in the supernatants after ON stimulation (with CBA technology). Experiments were performed in
triplicate and are representative of three independent experiments (error bars, SD). Two-tailed Student’s t tests were used to compare MMP-2-treated DCs to
DCs incubated with the vehicle control (for active and HI MMP-2) or the inhibitor alone (for MMP-2+inh).
See also Figure S1.to MMP-9-treated cells). Specificity for TLR2 was controlled
using TLR2-negative cells (Figure 5A). Similarly, TLR2 and
MyD88 immunoprecipitated with MMP-2 when moDCs were
pretreated with MMP-2 (Figure 5B; (p < 0.03 compared to
MMP-9-treated cells). Immunoprecipitation assays using an iso-1858 Cell Reports 9, 1856–1870, December 11, 2014 ª2014 The Auttype antibody control confirmed binding specificity (Figure 5C).
Total cell lysates were used as positive controls to demonstrate
TLR2 specific blotting (Figures 5D and 5E).
Biacore experiments further confirmed a physical association
between MMP-2 and TLR2. A high-affinity interaction with anhors
equilibrium affinity constant (KD) of 3.22 3 10
8 M, which falls
within the range for other TLR/ligand binding affinities (Akashi
et al., 2003; Rutz et al., 2004) was measured. Altogether, these
results confirm that MMP-2 directly interacts with TLR2, which
leads to the recruitment of and association with MyD88.
TLR2 Expression Is Sufficient for MMP-2-Mediated DC
Activation
TLR2 forms heterodimers with TLR1, TLR6, and potentially TLR4
(Lee et al., 2004; Takeda et al., 2002). We addressed whether
TLR2 required heterodimerization with one of these additional
TLRs in order to be triggered by MMP-2. Untransfected wild-
type (WT) HEK cells as well as HEK cells transfected with plas-
mids encoding human TLR1, TLR4, or TLR6 were not activated
by MMP-2 (Figures 6A–6D). On the other hand, HEK293 cells
transfected with the TLR2 plasmid alone or cotransfected with
plasmids encoding TLR2 and TLR1, TLR4, or TLR6 (Figures
6E–6H) produced comparable amounts of IL-8 in response to
MMP-2, suggesting that TLR1, TLR4, and TLR6 are not required
for optimal cytokine production. Moreover, blocking TLR2 but
not TLR6 significantly inhibited MMP-2 stimulation of TLR2-ex-
pressing HEK293 cells (Figures 6E–6H; p < 0.000045). Overall,
these data strongly suggest that MMP-2 triggers TLR2 indepen-
dently of TLR1, TLR6, or TLR4.
We next formally demonstrated that MMP-2 requires TLR2 to
activate DCs by using TLR-deficient C57/BL6 mice. Bone-
marrow-derived DCs (BM-DCs) were cultured with murine
MMP-2 or controls. In the presence of either active or HI-
MMP-2, WT BM-DCs as well as TLR6/ and TLR7/ BM-
DCs secreted significant amounts of inflammatory cytokines
such as TNF-a (Figure S4A) or IL-6 (Figures S4B and S5A) and
upregulated OX40L (Figures S4C and S5B). TLR4/ BM-DCs
treated with MMP-2 secreted little to no inflammatory cytokines
(Figure S5A) but upregulated OX40L (Figure S5B), suggesting a
possible role for TLR4 in MMP-2-dependent triggering of cyto-
kine production in murine BM-DCs, unlike the human condition.
TLR2/ and MyD88/ BM-DCs were not activated by MMP-2
or the respective TLR2/6 and TLR2/1 agonists, MALP2 and
Pam3CSK4 (Figures S4A–S4C). As expected, MALP2 stimulated
WT BM-DCs, but not TLR2/, TLR6/, or MyD88/ BM-DCs,
whereas Pam3CSK4 stimulated WT and TLR6
/ BM-DCs, but
not TLR2/ or MyD88/ BM-DCs (Figures S4A–S4C). These
results were confirmed using CD11c-purified splenic DCs (Fig-
ures S6A andS6B). Of interest, humanMMP-2 strongly activated
TLR2-expressing murine DCs (Figures S7A and S7B). Therefore,
both active and HI-MMP-2 induce DCs to produce inflammatory
cytokines and to upregulate OX40L in a TLR2/MyD88-depen-
dent manner.
MMP-2 Triggers TLR2-Dependent Inflammation In Vivo
We next evaluated whether MMP-2 triggered TLR2 in vivo. First,
TLR-deficient C57/BL6 mice were injected intravenously (i.v.)
with human MMP-2, which we found induced the strongest
response by murine DCs in vitro. In addition, MMP-2 was heat-
inactivated before injection to follow its influence on TLR2 trig-
gering, without concern for effects due to its enzymatic activity.
Sera obtained from WT mice contained TNF-a (Figure 7A), IL-6
(Figure 7B), andMCP-1 (data not shown). However, sera derivedCell Refrom TLR2/ or MyD88/mice had no inflammatory cytokines
(p% 0.000000001 and p% 0.000000000002 for TNF-a and IL-6,
respectively; Figures 7A and 7B). Therefore, as shown in vitro, HI
MMP-2 induces an inflammatory response in vivo in a TLR2/
MyD88-dependent manner.
MMP-2 was then evaluated for its ability to physiologically
skew type 2 responses in vivo. CD45.1+ C57/BL6 mice were in-
jected i.v. with OVA323–339-specific CD45.2
+ CD4+ OT-II cells.
The next day, mice were injected subcutaneously (s.c.) footpad
with MMP-2 or with type 1 or type 2 polarizing adjuvants
(Poly[I:C] and alum, respectively) together with OVA protein. At
day 10, CD4+ cells from draining lymph nodes were purified
and restimulated in vitro with OVA323–339 peptide. Priming with
OVA and Poly(I:C) elicited high frequencies of OT-II cells produc-
ing IFN-g (Figure 7C), but not IL-13 (Figure 7E). In contrast, OT-II
cells primedwith alum or either active or HI-MMP-2 produced lit-
tle IFN-g, but significant levels of IL-13 (Figures 7C and 7D).
Serum collected at day 10 demonstrated higher levels of OVA-
specific immunoglobulin G2a (IgG2a) levels than IgG1 in
response to Poly(I:C) adjuvant. On the contrary, higher levels of
OVA-specific IgG1 than IgG2a where observed when either
alum or MMP-2 was used (Figure 7E). Significantly, these
MMP-2-induced TH2 responses were abrogated in TLR2-defi-
cient animals (Figure 7F). Together, these results establish that
MMP-2 polarizes type 2 immune responses in a TLR2-depen-
dent manner in vivo, and that this property is independent of
its enzymatic activity.
In summary, our data demonstrate that MMP-2 is a physiolog-
ical TLR2 ligand/agonist responsible for cytokine production and
OX40L upregulation on DCs through MyD88 and NF-kB activa-
tion, which has the capacity to skew TH2 responses in vivo.
DISCUSSION
MMP-2 modulates many physiological conditions including
promoting wound repair, tissue remodeling, and metastasis. In
the latter case, tumor-associated MMP-2 expression correlates
with later tumor stages, increased dissemination, and poorer
survival/prognosis (Egeblad and Werb, 2002; Hofmann et al.,
2000). General MMP inhibitors have failed in the clinic
probably because they were designed to block enzymatic activ-
ity, and it was not appreciated that enzymatically inactive
MMPs can directly dysregulate innate and adaptive immunity
as shown here.
We demonstrated that MMP-2 cannot only function as an anti-
genic target of tumor infiltrating T cells (Godefroy et al., 2005) but
can drive TH2 differentiation through inhibition of IL-12p70 pro-
duction and upregulation of OX40L expression by human DCs
(Godefroy et al., 2005, 2011). Interestingly, although MMP-2
enzymatic activity is necessary to block IL-12p70 production
by DCs (Godefroy et al., 2011), we demonstrated here that it
was not required for OX40L upregulation (Figure 1A) or inflam-
matory cytokine production (Figure 1B). Strikingly, both active
and inactive forms ofMMP-2 induced the same degree of inflam-
matory response in DCs (Figure 1). These findings indicate that
MMP-2 uses a multitude of mechanisms to modulate the im-
mune system, some of which are clearly independent of its
catalytic activity and speak to its ability to incapacitate effectiveports 9, 1856–1870, December 11, 2014 ª2014 The Authors 1859
Figure 2. Involvement of the NF-kB Pathway in MMP-2-Mediated Activation of Human moDCs
(A and B) MoDCs were incubated with or without either the WT or the mutant NEMO-binding domain (NBD) peptide (4 mM) for 30 min, prior to addition of MMP-2
(5 mg/ml) or controls. (A) Inflammatory cytokine levels were measured in supernatants the following day using CBA technology. (B) OX40L expression was
assessed by immunostaining at day 2.
(legend continued on next page)
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immune responses through multiple mechanisms. MMP-2 is not
alone in this sense as other MMPs possess noncatalytic func-
tions (reviewed in Kessenbrock et al., 2010). MMP-9, through
its enzymatically inactive hemopexin domain, promotes both
epithelial cell migration probably via MAPK and PI3K activation
(Dufour et al., 2008) and B cell survival after triggering a4b1
and CD44v, which induces intracellular signaling involving Lyn
and STAT3 (Redondo-Mun˜oz et al., 2010). The hemopexin
domain of MMP-12 plays amajor role in its antimicrobial function
(Houghton et al., 2009), and pro-MMP-1 (Conant et al., 2004) and
MMP-14 (Rozanov et al., 2004), respectively, inhibit the comple-
ment cascade and induce neuronal death in a noncatalytic
manner through inhibition of AKT dephosphorylation. Therefore,
numerous nonproteolytic functions are mediated by MMPs, and
the property of MMP-2 described in this study adds a new
dimension.
Our study is distinguishable from those cited above in that
MMP-2 specifically polarizes T cell immune responses through
manipulation of innate immune cells through pattern recognition
receptors: MMP-2 is a physiologic ligand for TLR2 on DCs. This
interaction, which does not require catalytic activity, leads to
OX40L upregulation and ensuing TH2 polarization (Figure 7; God-
efroy et al., 2011). This is consistent with previous work, demon-
strating that TLR2 triggering by microbial or synthetic ligands
can also skew immune responses toward a TH2 profile (Agrawal
et al., 2003; Dillon et al., 2004). Thus, MMP-2 appears to function
similar to endogenous signals released in response to infection
or tissue remodeling and injury, also referred to as ‘‘alarmins.’’
Alarmins are endogenous mediators, produced by several cell
types, that can activate and recruit effectors of innate and adap-
tive immunity (Oppenheim et al., 2007). Interestingly, some of
these share similar mechanistic pathways withMMP-2, suggest-
ing that alarmins in general serve an important physiological
function in the host, one that may become usurped in certain
conditions such as inflammation and tumorigenesis.
In some respects, our observation that MMP-2 modulates DC
function to polarize TH2 responses is analogous to what has
been described for TSLP, typically produced by epithelial cells
in response to helminths (Allen and Maizels, 2011). After trig-
gering its receptor (TSLPR), TSLP induces target cells to pro-
duce and release type 2 cytokines such as IL-4 (Siracusa et al.,
2011) and upregulate OX40L (Ito et al., 2005), hence promoting
protective antiparasite inflammatory TH2 cell differentiation.
However, we showed that TSLP-induced signaling differs from
MMP-2’s as the former was shown to activate NF-kB through
translocation of p50 (canonical pathway) and RelB (non-canoni-
cal pathway) into the nucleus, where they bind to atypical NF-kB-
like sites in the OX40L promoter (Arima et al., 2010). In contrast,
MMP-2 only activates components of the canonical NF-kB
pathway, i.e., NEMO, p50, and p65 (Figure 2). This divergence
might in part be related to the fact that MMP-2 induces OX40L
upregulation on both mDCs and moDCs (Figures 1A and S1A),
whereas TSLP does so only on primary mDCs (Akamatsu(C) MoDCs were stimulated with 5 mg/ml MMP-2 and were harvested at indicate
nuclear fractions. Results are represented as percentages of untreated cells.
(D) MoDCs were stimulated for 30 min with 5 mg/ml MMP-2 or controls, and NF-
performed in triplicate. Two-tailed Student’s t tests were used to assess inhibition
Cell Reet al., 2008; Arima et al., 2010), but not on moDCs (Figure S2).
Notably, TSLPR seems to be expressed by mDCs, but not or
minimally by moDCs (Akamatsu et al., 2008), whereas TLR2 is
expressed by both subsets (Figure 3B). These different receptors
and their expression patterns could therefore account for distinct
signaling patterns between MMP-2 and TSLP.
Other TH2-skewing alarmins include cytokines such as IL-25
(Saenz et al., 2010) or IL-33 (Moro et al., 2010; Neill et al.,
2010), which drive the production of type 2 cytokines when
mounting antiparasite immune responses or during various dis-
orders, such as allergic and autoimmune diseases. IL-33 can
be rapidly released during tissue injury (Cayrol and Girard,
2009; Ohno et al., 2009) and is involved in tissue repair after
infection by the hookworm parasite Nippostrongylus brasiliensis
(Wills-Karp et al., 2012). Similarly, HMGB1 has been described
not only as an alarmin that can drive the pathogenesis of inflam-
matory and autoimmune diseases (Harris et al., 2012), but also
as a potential mediator in the skin wound healing process in a
collagen synthesis-dependent manner (Zhang et al., 2012).
In addition to HMGB1, other alarmin-like molecules stimulate
TLRs in vivo. Similar to MMP-2, some of these trigger TLR2.
Interestingly, two of them, versican and biglycan, are also com-
ponents of the extracellular matrix. Versican, a large proteogly-
can produced by tumor cells, can activate myeloid cells and
induce the production of proinflammatory cytokines through
TLR2/TLR6 complexes thereby inducing metastasis (Kim et al.,
2009). MMP-2, in contrast, seemingly triggers TLR2 indepen-
dently of coreceptors including TLR6, both in human (Figures
3, 4, and 6) and murine cells (Figures 7 and S4). TLR4 has also
been shown to dimerize with TLR2 (Lee et al., 2004; Popovic
et al., 2011; Schaefer et al., 2005). Indeed, the proteoglycan bi-
glycan seems to activate MyD88 and TRIF pathways through
TLR2/TLR4 heterodimers, leading to enhancement of T cell
priming and autoimmune perimyocarditis (Popovic et al., 2011;
Schaefer et al., 2005). However, TLR4 did not seem to be
involved in MMP-2-dependent triggering of human TLR2
because HEK293 cells transfected with the plasmid encoding
TLR2 alone or in combination with TLR4 responded similarly to
MMP-2 (Figure 6). Likewise, WT and TLR4/ splenic DCs ex-
hibited comparable MMP-2-induced responses in terms of
cytokine production (Figure S4A) and OX40L upregulation (Fig-
ure S4B). However, TLR4/ BM-DCs displayed partially
impaired cytokine production (Figure S3A), even though they still
upregulated OX40L (Figure S3A), suggesting that certain murine
DC subsets may utilize TLR4 for optimal MMP-2-mediated TLR2
signaling. MMP-2 did not trigger TLR2/TLR1 heterodimers as
HEK293 cells transfected with a plasmid encoding both TLR2
and TLR1 versus TLR2 alone did not further increase MMP-2-
mediated responses (Figure 6). Furthermore, Pam3CSK4
(TLR2/TLR1 agonist) did not induce OX40L in DCs (Figure 3A),
suggesting that this heterodimer does not participate in OX40L
regulation. Altogether, these results suggest that MMP-2 trig-
gers TLR2 homodimers or heterodimers with an unidentifiedd times. Levels of NF-kB components were measured in moDC cytosolic and
kB components were measured and represented as in (C). Experiments were
by the NBD peptide and NF-kB translocation into the nucleus (error bars, SD).
ports 9, 1856–1870, December 11, 2014 ª2014 The Authors 1861
Figure 3. MMP-2-Induced Activation of moDCs Depends on TLR2
(A) MoDCs were incubated with 5 mg/ml MMP-2 or various TLR agonists: Pam3CSK4 (100 ng/ml), Zymosan (1 mg/ml), MALP2 (100 ng/ml), polyI:C (10 mg/ml), LPS
(500 ng/ml), Flagellin (100 ng/ml), and R848 (50 mM). OX40L expression was assessed on moDCs 60 hr later.
(B) TLR2 expression by moDCs and mDCs was assessed by immunostaining. TLR2-transfected HEK cells and null HEK cells (TLR2) were used as positive and
negative controls, respectively.
(legend continued on next page)
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receptor. Analogously, the eosinophil-derived neurotoxin (EDN),
that is generated at sites of inflammation and associated with
parasitic infection and allergy, activates TLR2 independently of
TLR1 or TLR6 in DCs to enhance TH2 immune responses
(Yang et al., 2008). Finally, TLR10 is yet another TLR that can
dimerize with TLR2 (Guan et al., 2010; Hasan et al., 2005). Phylo-
genetic studies indicate that TLR10 is most related to TLR1 and
TLR6 (Chuang and Ulevitch, 2001). But, in comparison with
these two latter TLRs, TLR10 is expressed in a highly restricted
fashion, essentially by B cells and pDCs (Hasan et al., 2005),
making it unlikely to be involved in MMP-2/TLR2-dependent
TH2 polarization. Furthermore, TLR10, alone or in cooperation
with TLR2, failed to activate typical TLR-induced signaling,
including NF-kB or IL-8 (Guan et al., 2010).
In addition to the coreceptors described above, TLR2 can uti-
lize accessory receptors that are thought to enhance ligand de-
livery and/or contribute to cytoplasmic signaling. These include
CD14, CD36, and integrin b3. CD14 directly binds Pam3CSK4
and delivers it to TLR2, substantially increasing the sensitivity
of TLR2 responses (Vasselon et al., 2002, 2004). CD14 is not
expressed on moDCs (data not shown) and is therefore unlikely
to be involved in TLR2 triggering by MMP-2. CD36 can mediate
the sensing of some agonists through triggering of the
heterodimer TLR2/TLR6 (Hoebe et al., 2005). MMP-2-depen-
dent triggering of TLR2 does not involve TLR6, and thus
we postulate that CD36 is not implicated. The integrin chain
b3 can participate in sensing bacterial lipopeptides when
associated with TLR2 (Gerold et al., 2008). It can also interact
with MMP-2 directly via its hemopexin domain (Brooks et al.,
1996; Godefroy et al., 2005). A recombinant version of this
MMP-2-derived domain, rhPEX, induced neither inflammatory
cytokine production nor OX40L upregulation by moDCs (data
not shown), hence making b3 unlikely to participate in the
MMP-2-mediated model.
Biacore experiments, which demonstrated a direct high-affin-
ity interaction between MMP-2 and TLR2 (KD = 3.22 3 10
8 M)
also support a MMP-2/TLR2 direct interaction. Although addi-
tional potential receptors could further increase this affinity,
such a KD value falls within other TLR/ligand binding ranges.
For instance, the KD for the interaction between TLR9 and CpG
DNA is around 200 nM (Rutz et al., 2004), which is significantly
higher than for the MMP-2/TLR2 interaction. As another
example, the KD for LPS binding to TLR4 (taking into account
the interaction with MD2) is approximately 3 nM (Akashi et al.,
2003).
Of note, the doses of MMP-2 used both in vitro and in vivo
(from 0.5 to 5 mg/ml) are consistent with the physiological
concentrations reported in pathological conditions such as in
tumors and in the blood of cancer patients (Incorvaia et al.,
2007; Schmalfeldt et al., 2001). Therefore, it is not surprising
that supernatants derived from MMP-2-secreting melanoma
cells induced NF-kB activation and OX40L upregulation in(C and D) MoDCs were incubated with blocking Abs or isotype control for 30 min
secretion was measured in supernatants from three donors the following day
preincubated with an isotype control. Two-tailed Student’s t tests were used t
immunostaining at day 2.
Error bars, SD. See also Figures S2 and S4.
Cell Reboth TLR2-expressing HEK cells and moDCs (Figures S3C–
S3G), further reinforcing the physiological relevance of this
mechanism.
A fundamental question highlighted by our study is why
MMP-2 triggers inflammatory TH2 responses. In addition to
participating in controlling parasitic infections, TH2 cells may
generally contribute to wound healing following inflammation
(Bian and Sun, 1997). MMP-2 is upregulated by several stromal
cells of repairing tissues. MMP-2-induced inflammatory TH2
cells produce cytokines (TNF-a, IL-4, and IL-13) that are essen-
tial for major steps during wound healing, such as angiogenesis
(Kulbe et al., 2012; Larsen et al., 2012), enhancing the production
of growth factors like EGF (DeNardo et al., 2009), and antiapop-
totic functions (Di Stefano et al., 2010). Therefore, tissue repair
functions of MMP-2 might, at least in part, be due to its ability
to drive TH2 immune responses. In this respect, it should be
pointed out that other alarmins including IL-33/TFF2 and
HMGB1 are also involved in wound-healing processes (Wills-
Karp et al., 2012; Zhang et al., 2012).
Our findings suggest that MMP-2 could be uniquely targeted
in numerous conditions. Blocking antibodies to MMP-2 and/or
TLR2 as well as small molecule inhibitors of the MMP-2/TLR2
interaction could be applied to prevent TH2 skewing in metasta-
tic disease. By using it as an adjuvant, and in combination with
antigens, MMP-2-triggered OX40L expression and ensuing
TH2 polarization could limit the development of destructive TH1
or TH17 inflammatory or autoimmune diseases. Similarly,
MMP-2-mediated signaling either through direct injection or
through mimics could promote wound healing. The confirmation
of these proposed functions will require further investigation
in vivo in disease-specific models. In summary, the discovery
of these MMP-2 functions adds to the significance of stroma-
derived alarmins as potentiators of inflammatory responses
in vivo.
EXPERIMENTAL PROCEDURES
Monocyte-Derived Dendritic Cell Preparation and Activation
Peripheral blood mononuclear cells (PBMCs) were purified from anonymous
healthy donor blood (purchased from the New York Blood Center). PBMCs
were plated at 403 106 cells/10ml/dish in complete RPMI with 5% pooled hu-
man serum. Cells were allowed to adhere for 2 hr at 37C. Nonadherent cells
were removed. The adherent monocyte-enriched fraction was supplemented
with 100 UI/ml rhGM-CSF and 300 UI/ml rhIL-4 (R&D Systems) on days 0, 2,
and 4. Immature DCs were harvested on day 5 and matured/stimulated using
various TLR agonists or MMP-2. Secretion of IL-12p70, TNF-a, IL-6, and IL-8
by DCs was assessed using the Human Inflammatory Cytokine Cytometric
Bead Array kit (CBA; BD Pharmingen).
Mice
TLR2/, TLR4/, TLR6/, TLR7/, MyD88/, and WT C57/BL6 were pro-
vided by Bali Pulendran (Emory Vaccine Center) and Sergio Trombetta (Cancer
Institute, NYULMC) and initially originate from Taconic and Jackson Labora-
tories. Mice were housed under specific-pathogen-free conditions andbefore adding MMP-2 (0.5 and 5 mg/ml) or controls. (C) Inflammatory cytokine
. Results are represented as percentages of 5 mg/ml MMP-2-treated cells
o assess TLR-dependent inhibition. (D) OX40L expression was evaluated by
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Figure 4. MMP-2-Induced Activation of HEK Cells Depends on TLR2
(A–C) (A) TLR2-transfected HEK-Blue cells, (B) parental Null-HEK-Blue cells, or (C) TLR4-transfected HEK-Blue cells were preincubatedwith TLR-blocking Abs or
an isotype control and subsequently stimulated with MMP-2 (0.5 and 5 mg/ml) or controls. After 20 hr, IL-8 production and NF-kB activation were measured as
described in Experimental Procedures. Two-tailed paired Student’s t tests were used to assess TLR-dependent inhibition.
(D–F) OX40L expression was evaluated by immunostaining at day 2 after indicated treatments.
Error bars, SD. See also Figure S4.
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Figure 5. MMP-2 and TLR2 Coimmunoprecipitate
(A andB) 106moDCs or TLR2-transfected HEK cells (equivalents per lane) were incubated for 20minwith or without 5 mg/mlMMP-2 orMMP-9 before being lysed.
Untransfected and TLR4-transfected HEK cells were used as negative controls. TLR2 (A) andMMP-2 (B) were immunoprecipitated using specific Abs and protein
G-agarose.
(C) An isotype control was used to control the specificity of the immunoprecipitations. Western blots for MMP-2 (z70 kDa), TLR2 (z85 kDa), and MyD88
(z35 kDa) were then performed.
(D and E) Total lysates were used to confirm Ab specificity. Null-HEK-Blue and TLR4-HEK-Blue cells were used as a negative control (D, lane 1; E, lanes 1, 2,
5, and 6). TLR2-HEK-Blue cells preincubated with 5 mg/ml MMP-2 were used to control for MMP-2, TLR2, or MyD88 blotting, respectively (D, lane 2; E,
lanes 3 and 4).maintained in compliance with institutional and federal regulatory guidelines. A
IACUC approval was obtained for this study. Mouse BM-DCs were generated
as described previously (Lutz et al., 1999). Briefly, 2 3 106 bone marrow cells
were cultured in media supplemented with 20 ng/ml rmGM-CSF (Invitrogen)
and differentiated DCs were used for experiments between days 8 and 9.
BM-DCs were incubated overnight with 1 or 5 mg/ml of recombinant murine
MMP-2 or MMP-9 (active and heat-inactivated forms) as well as TLR agonists
for controls. Cytokines released in the supernatant were quantified by CBA
analysis. OX40L expression was assessed 2 days later by immunostaining.
For in vivo experiments, 5 mg HI hMMP-2, 100 mg Pam3CSK4, 2 mg LPS, or
controls were administrated i.v. into WT, TLR2/, or MyD88/ C57/BL6
mice. Blood was drawn 2 hr later, and sera were tested for IL-6, TNF-a, and
MCP-1 contents by CBA analysis. In in vivo skewing experiments, CD45.1+
C57/BL6 mice were transferred i.v. with 3 3 106 CD45.2+ OVA-specific
CD4+ OT-II cells. One day later, mice were inoculated s.c. footpad with
100 mg of LPS-free OVA protein (Seikagaku) together with MMP-2, 50 mg
Poly (I:C) (InvivoGen), or 1 mg Alum (InvivoGen). Ten days later, blood and
footpad-draining lymph nodes (popliteal, inguinal, and axillary lymph nodes)Cell Rewere harvested. In some experiments, lymph nodes cells suspension was re-
stimulated with 2 mg/ml OVA323–339 peptide (produced by the proteomics
resource center at The Rockefeller University) in the presence of 10 mg/ml
BFA (Sigma) for 6 hr, followed by intracellular IFN-g staining. In other experi-
ments, 2 3 105 bead-purified CD4+ T cells (Miltenyi) were coculture in vitro
with 4 3 104 splenic CD11c+ bead-purified (Miltenyi) DCs in the presence of
2 mg/ml OVA323–339 peptide, and IL-13 ELISA (eBioscience) was performed
on the culture supernatants 18 hr later. OVA-specific IgG1 and IgG2a levels
were assessed in the blood by ELISA (R&D Systems).
Reagents
Purified endotoxin-free human andmurineMMP-2 aswell as its corresponding
buffer (also referred as vehicle control herein) were purchased from Enzo/
Biomol. MMP-2 was inactivated either by heating at 56C for 45 min or by pre-
incubation with the MMP-2 inhibitor III at 100 nM (Calbiochem) for 20 min.
rhMMP-9 and rmMMP-9were purchased fromCalbiochem andR&DSystems,
respectively. rhGM-CSF and rhIL-4 were purchased from Immunex and R&D
Systems, respectively. Pam3CSK4, MALP2, and Flagellin were from Imgenex.ports 9, 1856–1870, December 11, 2014 ª2014 The Authors 1865
(legend on next page)
1866 Cell Reports 9, 1856–1870, December 11, 2014 ª2014 The Authors
Figure 7. MMP-2 Triggers In Vivo Inflammation and TH2 Polarization in a TLR2-Dependent Manner
(A and B) WT, TLR2/, or MyD88/ C57/BL6 mice were injected i.v. (tail vein) with 5 mg/ml MMP-2 or controls and plasma was analyzed for TNF-a and IL-6.
(C–E) CD45.1+ C57/BL6 mice were transferred i.v. with 3.106 CD45.2+ OVA-specific CD4+ OT-II cells. The next day, mice received 100 mg OVA protein alone or
together with 5 mg/ml MMP-2, 50 mg Poly (I:C), or 1 mg Alum s.c. (footpads). Blood and footpad-draining lymph nodes (popliteal, inguinal, and axillary) were
harvested 10 days later. (c) Draining lymph node cell suspension was restimulated for 6 hr with 2 mg/ml OVA323–339 in the presence of 10 mg/ml BFA. Shown is
IFN-g production byDAPI/CD3+/CD8/CD45.2+/Va2+ gated cells. Graphs are representative of two similar experiments (with four animals total). (D and F) Bead-
purified lymph node-derived CD4+ T cells were restimulated in vitro with bead-purified CD11c+ DC (1:5 ratio) and 2 mg/ml OVA323–339 peptide. PMA/ionomycin
was used as a positive control for cytokine secretion. Eighteen hours later, IL-13 secretion was measured by ELISA. Shown is the mean ± SD of two experiments
with a total of five to six animals. (E) OVA-specific IgG1 and IgG2a levels were assessed in the serum by ELISA. Shown is the ratio of IgG1/IgG2a as themean ±SD
of five to six animals in two different experiments. In all cases, two-tailed paired Student’s t tests were used to compare MMP-2 conditions to the vehicle control
(buffer).Zymosan and ultrapure LPS were from InvivoGen. Poly(I:C) was from
Amersham. R848 was from 3M Pharmaceuticals. Inflammatory cytokines
were quantified using CBA kits (BD Biosciences). The nuclear extraction as
well as the TransAM NF-kB ELISA kits (Active Motif) were used according toFigure 6. MMP-2 Activates TLR2-Transfected HEK Cells
WT HEK cells were or were not transfected with plasmids encoding human TLR
transfection reagent. Twenty-four hours later, cells were preincubated with blocki
in supernatants was evaluated after O/N culture. Results are represented as a me
MMP-2 conditions to the vehicle control (buffer).
Cell Rethe manufacturer’s instructions. The cell-permeable NEMO-binding domain
inhibitory peptide (DRQIKIWFQNRRMKWKKTALDWSWLQTE) and its mutant
(DRQIKIWFQNRRMKWKKTALDASALQTE) were from Calbiochem. Protein
G-agarose (Pierce) was used according to the manufacturer’s instructions.1, TLR2, TLR4, TLR6, TLR1, and 2, alone or in combination using FuGene HD
ng Abs before addition of 5 mg/ml MMP-2 or indicated controls. IL-8 production
an of triplicates ±SD. Two-tailed paired Student’s t tests were used to compare
ports 9, 1856–1870, December 11, 2014 ª2014 The Authors 1867
Plasmid Preparation and Transfection
Plasmids encoding both GFP and TLR1, TLR2, TLR4, or TLR6 (pUNO-hTLR-
GFP), TLR2, and TLR1 (pDUO-hTLR1/TLR2) as well as TLR2 and TLR6
(pDUO-hTLR2/TLR6) were purchased from InvivoGen. To limit endotoxin
contamination, plasmids were purified using the EndoFree Plasmid Maxi kit
(QIAGEN). FuGene HD transfection reagent (Promega) was used at a re-
agent/DNA ratio of 3:1.
Antibodies
PE-conjugated antibody (Ab) to OX40L (mouse mAb 11C3.1) was from
BioLegend. Flow cytometry Ab to TLR2 (mouse mAb 1030A5.138) was from
Abnova. Abs to TLR2 (mouse mAb TL2.1) and MMP-2 (mouse mAb 101724)
used for immunoprecipitation were from Abcam and R&D Systems, respec-
tively. Western blot Abs to TLR2 (rabbit pAb), MMP-2 (rabbit pAb H-76), and
MyD88 (rabbit pAb) were from Abcam, Santa Cruz Biotechnology, and Cell
Signaling Technology, respectively. HRP-linked anti-rabbit IgG (Cell Signaling)
were used as a secondary Ab before chemiluminescent detection (ECL Plus,
Amersham Biosciences). Blocking Abs for TLR2 (rat IgG pAb) and TLR6 (rat
IgG pAb) were from InvivoGen. Abs against murine CD11c (Armenian hamster
mAb N418, allophycoerythrin conjugated) and OX40L (rat mAb RM134L, PE
conjugated) were from BioLegend.
Biacore
Binding experiments were performed on Biacore 3000 at 25C by Precision
Antibodies Company. 400RU of TLR2 (R&D Systems) was captured on the
flow cell 2. MMP-2 was flowed over the chip at variable concentrations. Bind-
ing of MMP-2 to TLR2 was monitored in real time. Full kinetic analysis was
performed using 50 nM MMP-2, followed by serial dilutions. The equilibrium
affinity constant (KD) was calculated by steady-state kinetic analysis.
Statistical Analysis
Separate analyses were performed for each experiment individually and take
into account paired observations within donors when appropriate. For three-
group comparisons (e.g., isotype, anti-TLR2, or anti-TLR6), analyses of
variance were performed for an overall comparison among independent
groups, and t tests were then used for specific pairwise comparisons between
groups. Two-sided statistical tests were performed at an overall alpha-level of
0.05. Details for each analysis are provided in the figure legends. p values%
0.05 (*) were considered statistically significant.
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